Drug Details

General Information of the Drug (ID: DR0234)
Name
Empagliflozin
Synonyms
Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; Empagliflozin (BI 10773); BI-10773; BI10773; UNII-HDC1R2M35U; HDC1R2M35U; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; CHEBI:82720; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol; Empagliflozin [USAN:INN]; MFCD22566222; Jardiance (TN); (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; Tube106; (S)-Empagliflozin D4; BI-10773;Empagliflozin; Empagliflozin (BI10773); C23H27ClO7; SCHEMBL899986; GTPL4754; CHEMBL2107830; Empagliflozin (JAN/USAN/INN); AMY1858; EX-A414; BDBM150162; BBL104150; CE0108; s8022; STL557964; US8980829, EMPAGLIFLOZIN; ZINC36520252; AKOS024464680; CCG-269242; CS-0940; DB09038; DS-9824; PB23119; VA10802; AC-27643; HY-15409; SW219120-1; X5927; C22194; D10459; Q-4526; Q5373824; Empagliflozin (BI-10773;BI 10773;BI10773); (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Diabetes mellitus [ICD-11: 5A10] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 1.870 micromolh/L
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 0.259 micromol/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5 h
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability
Clearance
The apparent oral clearance of drug is 10.6 L/h
Elimination
After oral administration of radiolabeled empagliflozin approximately 41.2% of the administered dose was found eliminated in feces and 54.4% eliminated in urine
Half-life
The concentration or amount of drug in body reduced by one-half in 12.4 hours
Metabolism
The drug is metabolized via the glucuronidation
Vd
The volume of distribution (Vd) of drug is 73.8 L
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C23H27ClO7
PubChem CID
11949646
Canonical SMILES
C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
InChI
1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
InChIKey
OBWASQILIWPZMG-QZMOQZSNSA-N
CAS Number
CAS 864070-44-0
ChEBI ID
CHEBI:82720
TTD Drug ID
D06ALD
DrugBank ID
DB09038
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Metformin      Galega officinalis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 Initial combinations of empagliflozin + metformin for 24 weeks significantly reduced HbA1c versus empagliflozin once daily and metformin twice daily, without increased hypoglycemia, reduced weight versus metformin twice daily, and were well tolerated.
Target and Pathway
Target(s) Sodium/glucose cotransporter 2 (SGLT2)  Molecule Info  [3]
Reactome Hexose transport Click to Show/Hide
2 Na+-dependent glucose transporters
3 Inositol transporters
WikiPathways NRF2 pathway Click to Show/Hide
2 Nuclear Receptors Meta-Pathway
3 Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4754).
Reference 2 Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2016 Oct;39(10):1718-28.
Reference 3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
 Download Picture         KEGG Link